Table 1.
Demographics and baseline disease characteristics
| 25 mg (n = 1) | 50 mg (n = 3) | 75 mg (n = 3) | 100 mg (n = 10) | 125 mg (n = 10) | 150 mg (n = 10) | 175 mg (n = 3) | All patients (n = 40) | |
|---|---|---|---|---|---|---|---|---|
| Age, years | 50 (50–50) | 52 (51–64) | 53 (48–63) | 58 (39–65) | 54 (26–63) | 55 (39–65) | 51 (51–64) | 54 (26–65) |
| Sex | ||||||||
| Female | 1 (100) | 3 (100) | 3 (100) | 10 (100) | 10 (100) | 10 (100) | 3 (100) | 40 (100) |
| ECOG performance status | ||||||||
| 0 | 1 (100) | 3 (100) | 2 (66.7) | 4 (40.0) | 10 (100) | 9 (90.0) | 3 (100) | 32 (80.0) |
| 1 | 0 | 0 | 1 (33.3) | 6 (60.0) | 0 | 1 (10.0) | 0 | 8 (20.0) |
| Time since first diagnosis, years | 10.9 (10.9–10.9) | 5.2 (1.7–11.9) | 5.9 (2.4–12.0) | 9.6 (4.9–20.3) | 6.8 (1.4–20.1) | 11.3 (1.0–19.6) | 8.2 (8.2–10.5) | 8.8 (1.0–20.3) |
| Tumor stage at study entry | ||||||||
| IV | 1 (100) | 3 (100) | 3 (100) | 10 (100) | 10 (100) | 10 (100) | 3 (100) | 40 (100) |
| Previous therapy | ||||||||
| Surgery | 1 (100) | 3 (100) | 3 (100) | 10 (100) | 10 (100) | 10 (100) | 3 (100) | 40 (100) |
| Radiotherapy | 1 (100) | 3 (100) | 3 (100) | 8 (80.0) | 5 (50.0) | 8 (80.0) | 3 (100) | 31 (77.5) |
| Chemotherapy | ||||||||
| 1–2 regimens | 0 | 0 | 2 (66.7) | 2 (20.0) | 4 (40.0) | 3 (30.0) | 2 (66.7) | 13 (32.5) |
| 3–6 regimens | 1 (100) | 0 | 1 (33.3) | 6 (60.0) | 4 (40.0) | 5 (50.0) | 1 (33.3) | 18 (45.0) |
| Endocrine therapy | ||||||||
| 1–2 regimens | 0 | 1 (33.3) | 2 (66.7) | 4 (40.0) | 4 (40.0) | 6 (60.0) | 3 (100) | 20 (50.0) |
| 3–6 regimens | 1 (100) | 0 | 1 (33.3) | 3 (30.0) | 3 (30.0) | 3 (30.0) | 0 | 11 (27.5) |
Data are n (%) or median (range)
ECOG Eastern Cooperative Oncology Group